Oculus Innovative Sciences' (OCLS) New Post-Dermal-Procedures Product Receives FDA 510(k) Clearance

August 24, 2016 6:17 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new post-dermal-procedures product.

Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from post­dermal procedures.

“Within my practice I utilize the Microcyn Technology (hypochlorous acid or HOCl) post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections. I find these HOCl products to be safer, non-cytotoxic and a more effective alternative to povidone-iodine and chlorhexidine. Now, with this approval from the FDA, I believe my peers will benefit from adding Microcyn-based products to their treatment protocols,” said Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, the Laser & Rejuvenation Center and Tennessee Clinical Research Center, all located in Nashville, Tennessee.

Oculus’ dermatology division, IntraDerm, will begin marketing the post­dermal-procedures product in the United States beginning in March 2017.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Add Your Comment